Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
-
Published:2020-07
Issue:7
Volume:31
Page:942-950
-
ISSN:0923-7534
-
Container-title:Annals of Oncology
-
language:en
-
Short-container-title:Annals of Oncology
Author:
Ferris R.L.ORCID, Haddad R., Even C., Tahara M., Dvorkin M., Ciuleanu T.E., Clement P.M., Mesia R., Kutukova S., Zholudeva L., Daste A., Caballero-Daroqui J., Keam B., Vynnychenko I., Lafond C., Shetty J., Mann H., Fan J., Wildsmith S., Morsli N., Fayette J., Licitra L.
Subject
Oncology,Hematology
Reference19 articles.
1. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study;Fitzmaurice;JAMA Oncol,2019 2. Head and neck cancer: changing epidemiology, diagnosis, and treatment;Marur;Mayo Clin Proc,2008 3. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC);Cohen;J Immunother Cancer,2019 4. Platinum-based chemotherapy plus cetuximab in head and neck cancer;Vermorken;N Engl J Med,2008 5. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody;Stewart;Cancer Immunol Res,2015
Cited by
271 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|